一种系统的方法，用于选择合适的阿维巴坦浓度与头孢他啶联合用于肉汤微量稀释法药敏试验。
A Systematic Approach to the Selection of the Appropriate Avibactam Concentration for Use with Ceftazidime in Broth Microdilution Susceptibility Testing.
机构信息
AstraZeneca Pharmaceuticals, Waltham, Massachussetts, USA.
AstraZeneca Pharmaceuticals, Waltham, Massachussetts, USA
出版信息
Antimicrob Agents Chemother. 2018 Jun 26;62(7). doi: 10.1128/AAC.00223-18. Print 2018 Jul.
Abstract
Selection of the avibactam concentration to combine with ceftazidime in susceptibility testing was determined using Gram-negative isolates with characterized β-lactamases predefined as susceptible or resistant, based on the known inhibition spectrum of avibactam. MIC values were determined by broth microdilution of ceftazidime with fixed concentrations and ratios of avibactam. A constant concentration of 4 μg/ml of avibactam was selected for susceptibility testing with ceftazidime because of its ability to correctly categorize susceptible and resistant isolates while minimizing categorical errors.
摘要
在药敏试验中选择与头孢他啶联合使用的阿维巴坦浓度，是基于阿维巴坦已知的抑制谱，使用具有特征性β-内酰胺酶的革兰氏阴性分离株来确定的，这些β-内酰胺酶预先被定义为敏感或耐药。通过肉汤微量稀释法，用固定浓度和比例的阿维巴坦来测定头孢他啶的 MIC 值。由于 4 μg/ml 的阿维巴坦能够正确分类敏感和耐药分离株，同时最大限度地减少分类错误，因此选择该浓度用于头孢他啶的药敏试验。
相似文献
1
A Systematic Approach to the Selection of the Appropriate Avibactam Concentration for Use with Ceftazidime in Broth Microdilution Susceptibility Testing.
Antimicrob Agents Chemother. 2018 Jun 26;62(7). doi: 10.1128/AAC.00223-18. Print 2018 Jul.
2
Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016.
Antimicrob Agents Chemother. 2017 Oct 24;61(11). doi: 10.1128/AAC.01045-17. Print 2017 Nov.
3
Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Asia-Pacific Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015.
Antimicrob Agents Chemother. 2018 Jun 26;62(7). doi: 10.1128/AAC.02569-17. Print 2018 Jul.
4
Validation of Sensititre Dry-Form Broth Microdilution Panels for Susceptibility Testing of Ceftazidime-Avibactam, a Broad-Spectrum-β-Lactamase Inhibitor Combination.
Antimicrob Agents Chemother. 2015 Aug;59(8):5036-9. doi: 10.1128/AAC.00021-15. Epub 2015 May 26.
5
Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015.
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.01814-18. Print 2019 Apr.
6
Ceftazidime-Avibactam Antimicrobial Activity and Spectrum When Tested Against Gram-negative Organisms From Pediatric Patients: Results From the INFORM Surveillance Program (United States, 2011-2015).
Pediatr Infect Dis J. 2018 Jun;37(6):549-554. doi: 10.1097/INF.0000000000001859.
7
Assessment of 30/20-Microgram Disk Content versus MIC Results for Ceftazidime-Avibactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa.
J Clin Microbiol. 2018 May 25;56(6). doi: 10.1128/JCM.01960-17. Print 2018 Jun.
8
In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012-15.
J Antimicrob Chemother. 2018 Oct 1;73(10):2777-2781. doi: 10.1093/jac/dky267.
9
In vitro activity of ceftazidime/avibactam against isolates of Enterobacteriaceae collected in European countries: INFORM global surveillance 2012-15.
J Antimicrob Chemother. 2018 Oct 1;73(10):2782-2788. doi: 10.1093/jac/dky266.
10
Comparison of methods to analyse susceptibility of German MDR/XDR Pseudomonas aeruginosa to ceftazidime/avibactam.
Int J Antimicrob Agents. 2019 Aug;54(2):255-260. doi: 10.1016/j.ijantimicag.2019.05.001. Epub 2019 May 7.
引用本文的文献
1
Aztreonam plus ceftazidime-avibactam for post-neurosurgical meningitis due to .
Antimicrob Agents Chemother. 2025 Aug 6;69(8):e0017225. doi: 10.1128/aac.00172-25. Epub 2025 Jun 2.
2
Impact of porin deficiency on the synergistic potential of colistin in combination with β-lactam/β-lactamase inhibitors against ESBL- and carbapenemase-producing .
Antimicrob Agents Chemother. 2024 Nov 6;68(11):e0076224. doi: 10.1128/aac.00762-24. Epub 2024 Oct 4.
3
Sulbactam-durlobactam susceptibility test method development and quality control ranges for MIC and disk diffusion tests.
J Clin Microbiol. 2024 Jan 17;62(1):e0122823. doi: 10.1128/jcm.01228-23. Epub 2023 Dec 14.
4
Integrated Transcriptomic and Metabolomic Mapping Reveals the Mechanism of Action of Ceftazidime/Avibactam against Pan-Drug-Resistant .
ACS Infect Dis. 2023 Dec 8;9(12):2409-2422. doi: 10.1021/acsinfecdis.3c00264. Epub 2023 Oct 25.
5
Optimal ceftazidime/avibactam dosing exposure against KPC-producing Klebsiella pneumoniae.
J Antimicrob Chemother. 2022 Oct 28;77(11):3130-3137. doi: 10.1093/jac/dkac294.
6
The Ins and Outs of Susceptibility Testing for New β-Lactam/β-Lactamase Inhibitor Combinations for Gram-Negative Organisms.
J Clin Microbiol. 2022 Jul 20;60(7):e0080721. doi: 10.1128/jcm.00807-21. Epub 2022 Apr 7.
7
Sigmoid Modeling To Define the Fixed Concentration of Enmetazobactam for MIC Testing in Combination with Cefepime.
Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0092621. doi: 10.1128/AAC.00926-21.
8
Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide.
Antimicrob Agents Chemother. 2020 Oct 20;64(11). doi: 10.1128/AAC.01433-20.
9
Activity of Ceftazidime-Avibactam against Isolates from Respiratory and Blood Specimens from Patients with Nosocomial Pneumonia, Including Ventilator-Associated Pneumonia, in a Phase 3 Clinical Trial.
Antimicrob Agents Chemother. 2020 Apr 21;64(5). doi: 10.1128/AAC.02356-19.
10
Evaluation of Antifungal Drug Combinations against Multidrug-Resistant Candida auris Isolates from New York Outbreak.
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.02195-19.
本文引用的文献
1
Distinctive Binding of Avibactam to Penicillin-Binding Proteins of Gram-Negative and Gram-Positive Bacteria.
Antimicrob Agents Chemother. 2015 Nov 16;60(2):752-6. doi: 10.1128/AAC.02102-15. Print 2016 Feb.
2
Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection.
Antimicrob Agents Chemother. 2015 Nov 2;60(1):368-75. doi: 10.1128/AAC.01269-15. Print 2016 Jan.
3
In vitro antibacterial activity of the ceftazidime-avibactam combination against enterobacteriaceae, including strains with well-characterized β-lactamases.
Antimicrob Agents Chemother. 2015 Apr;59(4):1931-4. doi: 10.1128/AAC.04218-14. Epub 2015 Jan 12.
4
In vitro susceptibility of characterized β-lactamase-producing strains tested with avibactam combinations.
Antimicrob Agents Chemother. 2015 Mar;59(3):1789-93. doi: 10.1128/AAC.04191-14. Epub 2014 Dec 22.
5
Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model.
Antimicrob Agents Chemother. 2014 Jun;58(6):3366-72. doi: 10.1128/AAC.00080-14. Epub 2014 Mar 31.
6
Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value.
J Chemother. 2014 Dec;26(6):333-8. doi: 10.1179/1973947813Y.0000000145. Epub 2013 Dec 6.
7
Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam.
Clin Infect Dis. 2013 May;56(9):1301-9. doi: 10.1093/cid/cit017. Epub 2013 Jan 18.
8
Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia.
J Antimicrob Chemother. 2013 Apr;68(4):900-6. doi: 10.1093/jac/dks468. Epub 2012 Nov 28.
9
Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor.
Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11663-8. doi: 10.1073/pnas.1205073109. Epub 2012 Jul 2.
10
The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach.
Clin Microbiol Infect. 2012 Mar;18(3):E37-45. doi: 10.1111/j.1469-0691.2011.03752.x. Epub 2012 Jan 20.
Zotero 插件